FDA approves the first marijuana-based drug

For the first time, the FDA has approved a medicine derived from marijuana for use in the United States. The drug is a purified solution of 100% cannabidiol (or CBD), a naturally occurring compound found in marijuana plants, and it will be used to treat patients with rare, devastating forms of childhood epilepsy.

CBD is not psychoactive, but the DEA still classifies it as a Schedule I controlled substance, just like marijuana, insisting that it has “no accepted medical use” and “a high potential for abuse.” Although the FDA has concluded that CBD does have a medical use (and a “negligible abuse potential”), it’s up to the DEA to reclassify it before it can be sold in pharmacies.

Laws, Seizures, and CBD: Although scientists had thought that CBD might protect against seizures since at least 2004, marijuana laws made researching the plant difficult. But in 2012 and 2013, stories began emerging about kids with Dravet’s syndrome (a severe form of childhood epilepsy) dramatically reducing their seizures with CBD. Dozens of states responded by legalizing CBD or expanding their medical access laws to cover epilepsy.

Legalization at the state level and greater attention from the public made researching CBD an easier lift, and a number of high-quality studies were launched to see if it could treat epilepsy that wouldn’t respond to other drugs. Ultimately, three gold-standard clinical trials convinced the FDA that CBD does indeed help with intractable seizures. This year marks the first time that a drug made from the marijuana plant itself has been approved as a safe and effective medical treatment.

The DEA Isn’t Feeling It: Unfortunately for epilepsy patients, the FDA can approve CBD for medical uses, but the DEA still has the final say over whether it’s legal. If the agency doesn’t move it off the Schedule I list of banned substances, it won’t be hitting pharmacy shelves any time soon. Industry experts and the drug manufacturer who pushed CBD through the FDA approvals process seem confident that the DEA will downgrade it within 90 days.

But, as recently as May, the DEA was fighting tooth and nail in federal court to keep CBD on the Schedule I list. Even stranger, technically CBD has never been a controlled substance—unlike the psychoactive THC compound, which has its own listing, the cannabidiol compound is not mentioned on any list of restricted drugs. Instead, in just 2016, the DEA banned CBD through the backdoor, by declaring it and anything else made from marijuana to be “marijuana extract,” and therefore inherently just as illegal.

How this muddle of science and regulations will play out is anyone’s guess, but now the ball is entirely in the DEA’s court.

ergot alkaloids
Morning glories may be a source of new psychedelics and medicines
Researchers have found that the symbiotic relationship between a fungus and a morning glory holds the potential for new psychedelic compounds and medicines.
cannabis cooking
Traditional Thai cannabis cooking is back on the menu
Cannabis cooking has long simmered in Thailand. With the ruling junta’s new drug policies, the traditional dish is now making its way onto restaurant plates.
Should psychedelics be patented
The issue of patents has riven the psychedelic field. A lawyer’s repository of psychedelic info may make sure the new field stays fair.
The DMT ‘elves’ people meet while tripping 
Why do so many people encounter these ‘elves’ after smoking large doses of DMT?
Frontline healthcare workers are going to receive psilocybin therapy 
University of Washington researchers are enrolling healthcare workers now in a psilocybin-assisted therapy study.
Up Next
Subscribe to Freethink for more great stories